NRXP revenueQ2 2026$1.10M
- QoQ
- +3.1%
NRXP revenue was $1.10M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and up 3.1% from the prior quarter. For the full fiscal 2025 it was $1.45M, compared with $0 in fiscal 2024.
NRX Pharmaceuticals Inc. (NRXP) financials
For the twelve months ended Jun 30, 2026, NRX Pharmaceuticals Inc. reported $3.61M of revenue and -$23.48M of net income.
- Revenue, TTM
- $3.61M
- Net income, TTM
- -$23.48M
- Net margin
- -649.7%
- Cash
- $26.69M
- P/S
- 28.50
- Market cap
- $103.0M
FY2023FY2025
FY2018FY2025
FY2020FY2024
NRXP revenue and earnings growth
NRXP net incomeQ2 2026-$16.52M
NRXP net income was -$16.52M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$17.58M a year earlier. For the full fiscal 2025 it was -$28.62M, compared with -$25.13M in fiscal 2024.
NRXP free cash flowQ2 2025-$4.03M
NRXP free cash flow was -$4.03M in fiscal Q2 2025 (ended Jun 30, 2025), compared with -$2.56M a year earlier. For the full fiscal 2024 it was -$10.64M, compared with -$21.66M in fiscal 2023.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.45M | $0 | $0 | - | - | - | - | - |
| Cost of revenue | $505.0K | $0 | - | - | - | - | - | - |
| Gross profit | $940.0K | $0 | - | - | - | - | - | - |
| Research and development | $3.78M | $6.20M | $13.37M | $17.03M | $20.26M | $10.63M | - | - |
| Selling, general and admin | $13.06M | $13.50M | $14.22M | $27.31M | $74.94M | $11.44M | - | - |
| Operating income | -$16.22M | -$18.50M | -$27.84M | -$44.34M | -$115.80M | -$51.39M | -$713.2K | -$1.01M |
| Interest expense | $671.0K | $230.0K | $120.0K | - | $18.0K | $56.0K | - | - |
| Pre-tax income | - | - | - | -$39.75M | -$93.06M | -$51.78M | $492.6K | $82.4K |
| Income tax | $0 | $0 | $0 | - | - | $17.8K | $84.2K | $16.3K |
| Net income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $408.4K | $66.1K |
| EPS, basic | -$1.34 | -$2.36 | -$3.98 | -$0.60 | -$1.98 | -$1.51 | -$0.11 | -$0.29 |
| EPS, diluted | - | - | - | -$0.60 | -$1.98 | -$1.51 | -$0.11 | -$0.29 |
| Diluted shares | - | - | - | 65.8M | 46.9M | 34.3M | 2.8M | 2.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.80M | $1.44M | $4.59M | $20.05M | $27.61M | $1.86M | $877.4K | $11.1K |
| Receivables | $161.0K | $0 | - | - | - | $831.4K | - | - |
| Current assets | $8.89M | $3.30M | $6.88M | $25.80M | $32.71M | $2.93M | $69.5K | $30.2K |
| Goodwill | $1.79M | $0 | - | - | - | - | - | - |
| Total assets | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M | $2.94M | $32.07M | $70.80M |
| Current liabilities | $28.58M | $21.86M | $19.05M | $15.59M | $11.92M | $46.16M | $622.4K | $567.4K |
| Short-term debt | - | - | $9.16M | $7.70M | - | - | - | - |
| Long-term debt | $0 | $5.01M | $0 | $2.82M | - | - | - | - |
| Total debt | $0 | $5.01M | $9.16M | $10.53M | - | - | $1.54M | $690.0K |
| Total liabilities | $28.89M | $26.87M | $19.05M | $18.41M | $11.92M | $46.71M | $2.57M | $1.26M |
| Shareholders' equity | -$15.94M | -$23.22M | -$11.73M | $7.41M | $20.81M | -$43.77M | -$4.84M | $5.00M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.70M | -$2.27M | -$792.7K | -$473.2K |
| Capital expenditures | - | $0 | $3.0K | $10.0K | $7.0K | $2.0K | - | - |
| Free cash flow | - | -$10.64M | -$21.66M | -$39.77M | -$37.71M | -$2.27M | - | - |
| Investing cash flow | -$2.81M | $0 | -$3.0K | -$10.0K | -$7.0K | -$2.0K | $40.25M | -$647.4K |
| Financing cash flow | $23.28M | $7.49M | $6.20M | $32.21M | $63.46M | $3.25M | -$39.46M | $682.5K |
| Stock-based compensation | $228.0K | $486.0K | $387.0K | $3.63M | $7.79M | $730.0K | - | - |
| Depreciation and amortization | $70.0K | $5.0K | - | - | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Net income growth, YoY | - | - | - | - | - | - | 517.9% | - |
| Gross margin | 65.1% | - | - | - | - | - | - | - |
| Operating margin | -1122.8% | - | - | - | - | - | - | - |
| Net margin | -1980.8% | - | - | - | - | - | - | - |
| Return on equity | - | - | - | -536.6% | -447.3% | - | - | 1.3% |
| Return on assets | -220.9% | -688.2% | -412.2% | -154.0% | -284.3% | -1760.4% | 1.3% | 0.1% |
| Current ratio | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 | 0.06 | 0.11 | 0.05 |
| Debt to equity | - | - | - | 1.42 | - | - | - | 0.14 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.10M | $1.07M | $1.20M | $242.0K | $0 | $0 | $0 | $0 | - | - | - | - |
| Cost of revenue | $675.0K | $631.0K | $408.0K | $97.0K | $0 | $0 | $0 | $0 | - | - | - | - |
| Gross profit | $426.0K | $437.0K | $795.0K | $145.0K | $0 | $0 | $0 | $0 | - | - | - | - |
| Research and development | $2.12M | $1.31M | $558.0K | $1.43M | $987.0K | $804.0K | $1.04M | $611.0K | $2.80M | $1.75M | $2.53M | $3.31M |
| Selling, general and admin | $4.75M | $3.81M | $4.57M | $2.81M | $2.74M | $2.94M | $2.60M | $2.41M | $4.25M | $4.25M | $1.87M | $2.49M |
| Operating income | -$6.50M | -$4.74M | -$4.62M | -$4.02M | -$3.73M | -$3.85M | -$2.43M | -$3.02M | -$7.05M | -$6.00M | -$4.41M | -$5.81M |
| Interest expense | $240.0K | $233.0K | $671.0K | $0 | $0 | $0 | $0 | $0 | $0 | $230.0K | $80.0K | $40.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$16.52M | -$1.43M | $360.0K | -$5.89M | -$17.58M | -$5.51M | -$9.08M | -$1.62M | -$7.90M | -$6.53M | -$4.33M | -$6.06M |
| EPS, basic | -$0.44 | -$0.04 | - | -$0.27 | -$0.98 | -$0.34 | - | -$0.15 | -$0.75 | -$0.74 | - | -$0.74 |
| EPS, diluted | - | - | - | - | - | - | - | - | - | -$0.74 | - | -$0.07 |
| Diluted shares | - | - | - | - | - | - | - | - | - | 8.9M | - | 81.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.69M | $6.71M | $7.80M | $7.18M | $2.91M | $5.55M | $1.44M | $1.65M | $1.90M | $1.32M | $4.59M | $8.90M |
| Receivables | $206.0K | $181.0K | $161.0K | $239.0K | - | - | $0 | - | - | - | - | - |
| Current assets | $29.16M | $7.36M | $8.89M | $11.95M | $4.59M | $7.26M | $3.30M | $4.11M | $4.88M | $3.35M | $6.88M | $13.09M |
| Goodwill | $1.79M | $1.79M | $1.79M | $610.0K | - | - | $0 | - | - | - | - | - |
| Total assets | $34.16M | $11.90M | $12.96M | $15.00M | $4.84M | $7.59M | $3.65M | $4.46M | $5.26M | $3.79M | $7.32M | $13.11M |
| Current liabilities | $33.87M | $25.18M | $28.58M | $40.59M | $40.45M | $32.75M | $21.86M | $20.30M | - | - | $19.05M | $19.33M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | $9.16M | $10.07M |
| Long-term debt | - | - | $0 | $0 | $0 | $0 | $5.01M | $2.98M | - | - | $0 | - |
| Total debt | - | - | $0 | $0 | $0 | $0 | $5.01M | $2.98M | - | - | $9.16M | $10.07M |
| Total liabilities | $34.33M | $25.72M | $28.89M | $40.75M | $40.45M | $32.75M | $26.87M | $23.28M | $23.66M | $18.86M | $19.05M | $19.33M |
| Shareholders' equity | -$170.0K | -$13.82M | -$15.94M | -$25.75M | -$35.62M | -$25.16M | -$23.22M | -$18.82M | -$18.39M | -$15.07M | -$11.73M | -$6.22M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.88M | -$4.29M | -$3.71M | -$2.89M | -$4.03M | -$3.48M | -$2.10M | -$2.31M | -$2.56M | -$3.67M | -$3.19M | -$4.56M |
| Capital expenditures | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | -$1.0K | $2.0K |
| Free cash flow | - | - | - | - | -$4.03M | -$3.48M | -$2.10M | -$2.31M | -$2.56M | -$3.67M | -$3.19M | -$4.57M |
| Investing cash flow | -$684.0K | -$213.0K | -$249.0K | -$2.56M | $0 | $0 | $0 | $0 | $0 | $0 | $1.0K | -$2.0K |
| Financing cash flow | $29.53M | $3.42M | $4.58M | $9.73M | $1.39M | $7.58M | $1.90M | $2.05M | $3.14M | $395.0K | -$1.12M | -$1.50M |
| Stock-based compensation | $139.0K | $151.0K | $81.0K | $68.0K | $67.0K | $12.0K | $43.0K | $104.0K | $97.0K | $242.0K | -$1.20M | $351.0K |
| Depreciation and amortization | $66.0K | $63.0K | $42.0K | $26.0K | $0 | $1.0K | $1.0K | $2.0K | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 38.7% | 40.9% | 66.1% | 59.9% | - | - | - | - | - | - | - | - |
| Operating margin | -590.8% | -444.0% | -384.4% | -1662.8% | - | - | - | - | - | - | - | - |
| Net margin | -1500.5% | -133.9% | 29.9% | -2433.9% | - | - | - | - | - | - | - | - |
| Current ratio | 0.86 | 0.29 | 0.31 | 0.29 | 0.11 | 0.22 | 0.15 | 0.20 | - | - | 0.36 | 0.68 |
Source: XBRL data NRX Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NRXP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NRXP | $3.61M | - | -$23.48M | -649.7% | $103.0M |
| AXSM | $865.27M | +54.2% | -$157.29M | -18.2% | $7.42B |
| RLMD | - | - | -$61.93M | - | $455.5M |
| VNDA | $229.28M | +8.1% | -$274.83M | -119.9% | $246.7M |
| CMPS | - | - | -$266.30M | - | $1.31B |
NRXP FAQ
6 questionsWhat is NRXP revenue?
NRX Pharmaceuticals Inc. (NRXP) reported $3.61M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $1.45M.Is NRXP profitable?
No. NRX Pharmaceuticals Inc. reported a net loss of $23.48M for the twelve months ended Jun 30, 2026.How much cash and debt does NRXP have?
NRX Pharmaceuticals Inc. reported $26.69M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NRXP gross margin?
NRX Pharmaceuticals Inc.'s gross profit was $1.80M on $3.61M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 49.9%.When did NRXP last report financial results?
The latest statements here come from NRX Pharmaceuticals Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this NRXP financial data come from?
Quantisnow builds these statements from the structured XBRL data NRX Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.